DanaFarber Cancer Institute Newswire (Page 9)

DanaFarber Cancer Institute Newswire (Page 9)

Comprehensive Real-Time News Feed for DanaFarber Cancer Institute. (Page 9)

Results 161 - 180 of 1,636 in DanaFarber Cancer Institute

  1. Ursula Matulonis, MD, named Brock-Wilson Family ChairRead the original story

    Dec 26, 2017 | PressReleasePoint

    Ursula Matulonis, MD , has been named the first incumbent of the Brock-Wilson Family Chair at Dana-Farber Cancer Institute. The newly established Chair was created to advance gynecologic oncology research and support a highly dedicated faculty member at Dana-Farber.

    Comment?

  2. Berkshire Bank Awards $14,000 to The Jimmy Fund & Dana Farber Cancer...Read the original story

    Dec 21, 2017 | PressReleasePoint

    Pittsfield, MA - Berkshire Bank, America's Most Exciting BankA , announced that in partnership with New England Sports Network , has awarded a $14,000 grant to The Jimmy Fund & Dana Farber Cancer Institute through the Berkshire Bank Exciting Assists Grant Program. Dr. Pasi Janne, Program Director, Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute accepted the contribution from Gary Levante, Berkshire Bank's Assistant Vice President of Community Engagement during NESN's broadcast of the Boston Bruins hockey game on December 16. To view this on air feature, please visit https://vimeo.com/247989570 The Exciting Assists Grant program runs through March 31, 2018 and raises funds to support three charitable causes.

    Comment?

  3. Atossa Genetics Names Scientific AdvisorRead the original story w/Photo

    Dec 21, 2017 | Contract Pharma Breaking News

    Carl Novina, MD, Ph.D., has been appointed as scientific advisor, Atossa Genetics Inc. a clinical-stage pharma company developing novel therapeutics and delivery methods for breast cancer. Dr. Novina is a leading researcher in the field of RNAi therapeutics.

    Comment?

  4. Results from Alliance Cabosun trial lead to Us Fda approval of extended indicationRead the original story w/Photo

    Dec 20, 2017 | PhysOrg Weblog

    The Alliance for Clinical Trials in Oncology , in conjunction with industry partner Exelixis, today announced that the U.S. Food and Drug Administration approved CABOMETYX tablets for the expanded indication of patients with advanced renal cell carcinoma . RCC is the most common form of kidney cancer in adults.

    Comment?

  5. 'I'm running out of time': Cancer patients struggle to get accepted to U.S. clinical trialsRead the original story w/Photo

    Dec 17, 2017 | The Toronto Star

    Patients are routinely excluded from testing potentially live-saving drugs for a host of reasons. Now, health experts are wondering whether eligibility criteria should be loosened.

    Comment?

  6. Special deliveryRead the original story w/Photo

    Dec 15, 2017 | Boston Herald

    US Army National Guard members from Officer Candidate School Class 85 start their cold walk to deliver holiday gifts to pediatric patients at Dana Farber Cancer Institute. Future U.S. Army leaders marched 4 miles in freezing temps yesterday to deliver an early Christmas to the children at Dana-Farber Cancer Institute.

    Comment?

  7. A sporting rally: SUNY Potsdam raises funds for staffera s cancer treatmentsRead the original story

    Dec 13, 2017 | Watertown Daily Times

    Alex Berking, an assistant athletic trainer at the school, recently underwent surgery to remove about 90 percent of a cancerous brain tumor. She will receive radiation and chemotherapy treatments in the months ahead to kill what's left.

    Comment?

  8. Dana-Farber/Brigham and Women's physician wins prestigious 2017...Read the original story w/Photo

    Dec 12, 2017 | Newswise

    ATLANTA Benjamin Ebert, MD, PhD, chair of Medical Oncology at Dana-Farber Cancer Institute in Boston has been named the recipient of the 2017 William Dameshek Prize from the American Society of Hematology for his seminal discoveries in multiple areas of non-malignant and malignant hematology. The William Dameshek Prize is awarded to an early-or mid-career hematologist who has made a recent outstanding contribution to the field of hematology.

    Comment?

  9. GlycoMimetics Reports Improvements in Median Overall Survival Versus...Read the original story

    Dec 12, 2017 | Customer Interaction Solutions

    GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase 1/2 Trial for GMI-1271 GlycoMimetics, Inc. today announced updated data from the Phase 1/2 trial evaluating the safety, tolerability and efficacy of GMI-1271 in patients with relapsed/refractory acute myeloid leukemia and in older adults with newly diagnosed AML, including the following conclusions: For patients with R/R AML treated at the Phase 2 dose and for whom median follow up was 6.6 months: Median overall survival was 9.4 months .

    Comment?

  10. Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinomaRead the original story

    Dec 5, 2017 | Nature Reviews Clinical Oncology

    Joaquim Bellmunt is at the Bladder Cancer Center at Dana-Farber Cancer Institute in Boston, USA, and is associate professor of medicine at the Harvard Medical School. He is an internationally respected leader in the fields of medical oncology and urological malignancies, and a recognized expert in the area of new drug development and immunotherapy.

    Comment?

  11. Study Identifies Agent That Can Reverse Resistance to Targeted Drug in Some Leukemia Cell TypesRead the original story w/Photo

    Dec 11, 2017 | Newswise

    ATLANTA After discovering how some hematologic cancer cells manage to elude death from a targeted therapy, Dana-Farber Cancer Institute scientists have double-crossed the cancer cells with a drug that renders them vulnerable to the targeted agent. At the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, the researchers presented laboratory findings that the drug azacitidine can reverse tumor cells' resistance to the targeted agent SL-401.

    Comment?

  12. Aileron Therapeutics Presents New Data on ALRN-6924 in Oral...Read the original story

    Dec 11, 2017 | Customer Interaction Solutions

    Aileron Therapeutics, the clinical-stage leader in the field of stapled peptides developing therapeutics for cancers and other diseases, today announced two oral presentations of preclinical data from collaborators on ALRN-6924 in T-cell lymphomas and acute myeloid leukemia . ALRN-6924, a stapled peptide therapeutic, is believed to be the first product candidate undergoing clinical evaluations that has been shown to disrupt both MDMX- and MDM2-mediated inhibition of the wild type p53 tumor suppressor gene.

    Comment?

  13. Low-dose treatment with Il2 across studies shows benefits in chronic graft-versus hostRead the original story w/Photo

    Dec 11, 2017 | PhysOrg Weblog

    Daily low doses of the immune signaling protein interleukin-2 can safely benefit patients who develop chronic graft-versus-host disease following stem cell transplants, including particular benefit in pediatric patients in one small study, report scientists from Dana-Farber Cancer Institute. Dana-Farber researchers, who have pioneered the use of IL-2 in post-transplant patients, presented four related abstracts at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.

    Comment?

  14. George William Burke, III, MD, FACS, Presented with the Albert Nelson ...Read the original story w/Photo

    Dec 11, 2017 | 24-7 Press Release

    Dr. Burke has been endorsed by Marquis Who's Who as a leader in the field of surgery and higher education -- Marquis Who's Who, the world's premier publisher of biographical profiles, is proud to present George William Burke, III, MD, FACS, with the Albert Nelson Marquis Lifetime Achievement Award. An accomplished listee, Dr. Burke celebrates many years' experience in his professional network, and has been noted for achievements, leadership qualities, and the credentials and successes he has accrued in his field.

    Comment?

  15. Sequencing offers clues to progression toward multiple myelomaRead the original story

    Dec 10, 2017 | PressReleasePoint

    Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma , a precursor to full-blown blood cancer that doesn't show outward symptoms. The next-generation sequencing project "will help to explain the biology of the disease and how it unfolds through time from asymptomatic stages to symptomatic ones," said Mark Bustoros, MD, a postdoctoral fellow in the lab of Irene Ghobrial, MD .

    Comment?

  16. Tracking how multiple myeloma evolves by sequencing DNA in the bloodRead the original story

    Dec 10, 2017 | PressReleasePoint

    Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, eventually, deliver more effective treatments.

    Comment?

  17. Rapid Responses, Few Adverse Effects Seen with Targeted Agent in Phase 1 Trial in Rare Blood DisorderRead the original story

    Dec 10, 2017 | PressReleasePoint

    In a Phase 1 trial, patients with an advanced or aggressive form of systemic mastocytosis , a rare blood disorder, had rapid and durable responses with few adverse effects following treatment with an investigational drug that targets the genetic mutation found in more than 90 percent of cases. The once-daily pill, BLU-285, targets a mutation called KIT D816V that is found in almost all cases of AdvSM, a disease that originates in mast cells, a type of white blood cell.

    Comment?

  18. Study explores use of checkpoint inhibitors after relapse from donor stem cell transplantRead the original story w/Photo

    Dec 10, 2017 | PhysOrg Weblog

    Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial in these patients of one such agent - nivolumab - indicate that along with signs of effectiveness, it also produced significant side effects at the dose initially studied.

    Comment?

  19. Rapid responses, few adverse effects in targeted agent in Phase1 trial in rare blood disorderRead the original story w/Photo

    Dec 10, 2017 | PhysOrg Weblog

    In a Phase 1 trial, patients with an advanced or aggressive form of systemic mastocytosis , a rare blood disorder, had rapid and durable responses with few adverse effects following treatment with an investigational drug that targets the genetic mutation found in more than 90 percent of cases. The once-daily pill, BLU-285, targets a mutation called KIT D816V that is found in almost all cases of AdvSM, a disease that originates in mast cells, a type of white blood cell.

    Comment?

  20. Bears rally behind Potsdam assistant athletic trainer diagnosed with cancerRead the original story

    Dec 10, 2017 | Ogdensburg Courier-Observer/Journal

    About a month ago, Alex Berking, an assistant athletic trainer at SUNY Potsdam, went to the Canton-Potsdam Hospital with headaches and vision problems. A few days later, she was undergoing surgery at the University of Vermont Medical Center to remove 90 percent of a cancerous brain tumor.

    Comment?